United States will present with metastatic breast cancer in an age group that already has the worst prognosis, no recommended routine screening practice, the least health insurance, and the most potential years of life," the authors concluded.
The JAMA article (Feb. 27) carried more poignancy: Its first author, Rebecca Johnson, M.D., director of the adolescent and young-adult oncology program at Seattle Children's Hospital, was diagnosed with breast cancer 17 years ago, at age 27.
The media treated the story with restraint. The Los Angeles Times ran it on page 8, and the New York Times on page 13. Nevertheless, many outlets could not resist getting quotes from worried women. "That's scary," a 27-year-old woman who already gets mammograms because of a family history told CBS Morning News.
Experts quickly admonished that routine mammography screening is not appropriate for women younger than 40 years, which is one of the conundrums of the paper.
"The principal observation of this article is a curiosity," said Berry, "but it has no policy or clinical implications. It doesn't begin to imply that women in this age group should be screened, for example, and not even the authors suggest that."
Johnson and coauthor Archie Bleyer, M.D., do suggest that women of all ages report any change in their breasts to a physician. "I hope our publication increases that awareness that you can't ignore a lump, discharge, or pain," said Bleyer, clinical research professor at Oregon Health and Science University in Portland. Berry agreed with that message, but with an important caveat: "It's far from clear that treating it [at the point where symptoms are apparent] would change the outcome. It's quite conceivable that the cat is already out of the bag," that is, the tumor has already spread to distant organs.
Johnson stressed that her research was "very preliminary. The trend we identified needs to be validated in other large databases-colleagues in Canada are already looking-and then we'll look at what might be underlying the trend. Are there environmental factors? Modifiable lifestyle factors? That will require a series of hypothesis-based research projects."
Bleyer said that no one knows what might be causing the increase. "It's probably a combination of factors: increased obesity, later childbirth, decreased or later breast-feeding, earlier menarche, and other aspects yet to be identified," he said.
Even if the effect is real, the numbers are small. In absolute terms, about 250 cases of metastatic breast cancer were diagnosed in U.S. women aged 25-39 years in 1976, compared with about 850 today. (The overall number of women in that age group went from about 22 million to about 30 million over the same period.) The increase in the incidence rate, from 1.53 to 2.90 cases per 100,000, or 1.37 case patients, could be caused by such factors as improved staging due to positron emission tomography scans and other sophisticated diagnostic imaging. "Better staging would easily explain all 1.37 [case patients] per 100,000," said Berry.
Screening might also contribute. "Not many women aged 25-39 get screened," said Berry, "but some do. It takes only a few to account for a statistically significant increase from 1 in 100,000."
One expert who is less inclined to explain away the JAMA findings is the National Cancer Institute's William of Cancer Epidemiology and Genetics, said that the JAMA results are "generally consistent with things that we and others have reported.
"They note that incidence rates are rising primarily among young women with estrogen receptor (ER)-positive breast cancers," said Anderson. "There's a negative trend for ER-negative disease. That's exactly the same divergent pattern that we reported in 2011" (see J. Natl. Cancer Inst. 2011; 103:1397-402) . Anderson cited analyses by his group and others showing that the decline in breast cancer diagnoses that occurred in the early 2000s, when mammography rates dropped off slightly and many women went off hormone replacement therapy, appears to have ended and that ER-positive disease is again increasing-not only in the United States but also perhaps in other countries. Moreover, several studies point to a long-term decline in rates of ER-negative disease.
Anderson's 2011 analysis found that, among women aged 30-49 years, the rate of ER-positive breast cancer increased 1.17% per year from 1992 to 2008, whereas the rate of ER-negative cancer decreased 2.42% per year. These trends were projected to continue over the next few years.
According to estimates of the American Cancer Society, some 230,000 U.S. women will receive a diagnosis of invasive breast cancer in 2013. Only about 5% of all cases are diagnosed in women younger than 40 years.
Berry believes that virtually all changes in incidence rates of breast cancer are associated with screening, measurement, or use of hormones. If ER-positive disease is going up and ER-negative disease is going down, Berry said, "the easiest answer is that pathologists have changed something [in how they measure hormone receptors], or mammography is changing the detection of the two types of breast cancer. Maybe digital mammography has an effect. "It's happening so rapidly, it would be a bit strange if this were etiological. If it were happening over 70 years, it would make more sense. But, then again, maybe something else is going on."
Anderson conceded that more sensitive ER tests or lower diagnostic thresholds for ER-positive cancers might contribute to the reduction in ER-negative disease. At the same time, he said, "statistically significantly different birth cohort deviations for ER-positive and ER-negative cancers are consistent with different trends in etiologically distinct entities." Anderson said that these patterns need to be confirmed but added, "If it is truly a cohort effect, certain reproductive, dietary, and hormonal risk factors must do different things to ER-positive and ER-negative breast cancers." For an example, he pointed to childbearing: "As parity goes down, ER-positive disease goes up while ER-negative disease goes down."
Ravdin said that obesity, too, could have a dual effect. He noted that results from the P-1 Breast Cancer Prevention Trial showed that obesity selectively increases the proportion of ER-positive breast cancer in premenopausal but not postmenopausal women. Then he added, "Perhaps speculating about the mechanisms of an effect that arguably may or may not be real is getting ahead of the game." They said that although data from animal, clinical, and prevention studies support the role of androgen in prostate cancer growth, proliferation, and progression, "results from serum-based epidemiologic studies in humans have been inconclusive, and . . . showed no association between serum androgen and prostate cancer risk."
That same year, a study from Istanbul, Turkey, amplified this conclusion. Published in volume 11 of Informa Healthcare, their study of 152 patients found no correlation between pattern of baldness and androgen levels in the blood.
However, researchers from the European Georges Pompidou Hospital in Paris, France, reached a different conclusion. Reporting on a study of 669 subjects in the Aug. 22, 2011, issue of Annals of Oncology, they found that patients with prostate cancer were twice as likely to have male pattern baldness, or androgenic alopecia (AA), at age 20 years.
